Primipaternity in multiparas as a predominant high risk factor for preeclampsia over prolonged birth intervals: A study of 33,000 singleton pregnancies in Reunion Island.

Objectives: To evaluate the relative importance of changing paternity ("primipaternity", direct inquiry with patients) in multiparas versus prolonged birth/pregnancy interval as risk factors for preeclampsia (PE) by a logistic regression model comparing the adjusted odds ratios of both exposures.

Design: Assessment of all consecutive singleton deliveries (from 22 weeks onwards) at South-Reunion University's maternity (Reunion Island, Indian Ocean) over 23 years (2001-2023) using an epidemiological perinatal database on obstetrical factors (264 items in total, of which, chronic or gestational hypertension, proteinuria, HELLP syndrome).

Results: Among the 53,572 multiparous singleton pregnancies, we identified 33,312 (62%) of multiparas who gave consecutive births, allowing calculation of birth intervals.

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.

MYC is one of the most important therapeutic targets in human cancer. Many attempts have been made to develop small molecules that could be used to curb its activity in patients, but most failed to identify a suitable direct inhibitor. After years of preclinical characterization, a tissue-penetrating peptide MYC inhibitor, called Omomyc, has been recently successfully used in a Phase I dose escalation study in late-stage, all-comers solid tumour patients.

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/lowdose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT.